Incyclix Bio
PrivateLast Round
Series B
Extension
Apr 8, 2026
Total Funding Raised
$52.25M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Incyclix Bio is a biotechnology company that develops small molecule inhibitors of cyclin-dependent kinases (CDKs) to treat patients with advanced and resistant cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Incyclix Bio Comparables
Compare Incyclix Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Avenzo Therapeutics | 91% | |
| Pyxa Pharmaceuticals | 83% | |
| Carrick Therapeutics | 83% | |
Incyclix Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Apr 8, 2026 | ||||
| Series B Extension | Aug 25, 2025 | ||||
| Series B | Mar 31, 2022 | ||||
| Seed | Aug 5, 2020 |
Key People
Founding team and executive leadership
Incyclix Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RA Capital Management | Series B, Series B Extension |
| Boxer Capital | Series B Extension, Series B |
| Hatteras Venture Partners | Series B, Series B Extension |
| Eshelman Ventures | Series B, Series B Extension, Seed |
| Cape Fear BioCapital | Series B, Series B Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 72% MoM.
- Jul 20, 2026
Open roles increased from 0 to 4, representing 31% of headcount.
Incyclix Bio Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Incyclix Bio's valuation, stock price, and market status.